News | May 11, 2023
Takeda pledges support to HAE patients through its ‘Sunrise patient support program’
Sunrise is built on four elements i.e., Awareness, Screening & Diagnosis, Treatment, and Maintenance Support
Sunrise is built on four elements i.e., Awareness, Screening & Diagnosis, Treatment, and Maintenance Support
Showcased digital innovations: MyPKFit, SYNAPSE and Athena at the G20 Health Working Group Meeting
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
The approval follows the positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in October 2022
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
Adynovate in combination with Mypkfit offers personalized treatment and enables HCPs and patients to monitor factor levels from home and help achieve optimum QOL outcomes
Recognition illustrates Takeda’s patient-centricity throughout its manufacturing and supply processes
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
Serina has over 17 years of experience in the biopharmaceutical industry
Acquisition adds Adaptate’s novel antibody-based ?? T-cell engager platform to Takeda’s Immuno-oncology portfolio built around the Innate Immune System
Subscribe To Our Newsletter & Stay Updated
